255 related articles for article (PubMed ID: 32582721)
41. Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin.
Shin DG; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
Yonsei Med J; 2016 Mar; 57(2):342-9. PubMed ID: 26847285
[TBL] [Abstract][Full Text] [Related]
42. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
[TBL] [Abstract][Full Text] [Related]
43. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A
Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420
[TBL] [Abstract][Full Text] [Related]
44. Non-vitamin K oral anticoagulants in hypertrophic cardiomyopathy patients undergoing catheter ablation of atrial fibrillation.
Creta A; Hunter RJ; Earley MJ; Finlay M; Dhinoja M; Sporton S; Chow A; Mohiddin SA; Boveda S; Adragao P; Jebberi Z; Matos D; Schilling RJ; Lambiase PD; Providência R
J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2626-2631. PubMed ID: 32639666
[TBL] [Abstract][Full Text] [Related]
45. Comparative safety of periablation anticoagulation strategies for atrial fibrillation: data from a large multicenter study.
Arshad A; Johnson CK; Mittal S; Buch E; Hamam I; Tran T; Shaw RE; Musat D; Preminger M; Sichrovsky T; Herweg B; Shivkumar K; Hummel J; Steinberg JS
Pacing Clin Electrophysiol; 2014 Jun; 37(6):665-73. PubMed ID: 24797604
[TBL] [Abstract][Full Text] [Related]
46. Immediate post-procedure bridging with unfractioned heparin versus low molecular weight heparin in patients undergoing radiofrequency ablation for atrial fibrillation with an interrupted oral anticoagulation strategy.
Loughlin G; Romaniega TD; Garcia-Fernandez J; Calvo D; Salgado R; Alonso A; Li X; Arenal A; González-Torrecilla E; Atienza F; Fernández-Avilés F
J Interv Card Electrophysiol; 2016 Mar; 45(2):149-58. PubMed ID: 26739484
[TBL] [Abstract][Full Text] [Related]
47. Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries.
Russo V; Attena E; Baroni M; Trotta R; Manu MC; Kirchhof P; De Caterina R
J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35807032
[TBL] [Abstract][Full Text] [Related]
48. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
49. Feasibility of Uninterrupted Direct Oral Anticoagulants with Temporary Switching to Dabigatran ("Dabigatran Bridge") for Catheter Ablation of Atrial Fibrillation.
Aoyama D; Miyazaki S; Hasegawa K; Kaseno K; Ishikawa E; Mukai M; Miyahara K; Aiki T; Matsui A; Yamaguchi J; Shiomi Y; Tama N; Ikeda H; Fukuoka Y; Morishita T; Ishida K; Uzui H; Tada H
Int Heart J; 2019 Nov; 60(6):1315-1320. PubMed ID: 31735780
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
51. Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis.
Liu XH; Gao XF; Chen CF; Chen B; Xu YZ
J Thromb Thrombolysis; 2020 Jul; 50(1):201-210. PubMed ID: 31686297
[TBL] [Abstract][Full Text] [Related]
52. Effects of uninterrupted dabigatran on the intensity of anticoagulation during atrial fibrillation ablation.
Osawa T; Mori H; Kawai A; Kawano D; Tsutsui K; Ikeda Y; Yamaga M; Sato A; Gatate Y; Hamabe A; Tabata H; Kato R; Matsumoto K
J Arrhythm; 2022 Feb; 38(1):58-66. PubMed ID: 35222751
[TBL] [Abstract][Full Text] [Related]
53. Nationwide survey of catheter ablation for atrial fibrillation: The Japanese catheter ablation registry of atrial fibrillation (J-CARAF)-A report on periprocedural oral anticoagulants.
Murakawa Y; Nogami A; Shoda M; Inoue K; Naito S; Kumagai K; Miyauchi Y; Yamane T; Morita N; Mitamura H; Okumura K;
J Arrhythm; 2015 Feb; 31(1):29-32. PubMed ID: 26336520
[TBL] [Abstract][Full Text] [Related]
54. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
55. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
[TBL] [Abstract][Full Text] [Related]
56. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
Gorczyca-Michta I; Wożakowska-Kapłon B
Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
[TBL] [Abstract][Full Text] [Related]
57. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
Trujillo TC; Dobesh PP; Crossley GH; Finks SW
Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
[TBL] [Abstract][Full Text] [Related]
58. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
59. Peri-procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: A meta-analysis.
Mao YJ; Wang H; Huang PF
Pacing Clin Electrophysiol; 2020 Oct; 43(10):1104-1114. PubMed ID: 32794584
[TBL] [Abstract][Full Text] [Related]
60. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
Fosbøl EL; Vinding NE; Lamberts M; Staerk L; Gundlund A; Gadsbøll K; Køber L; Gislason GH; Olesen JB
Europace; 2018 Jun; 20(6):e78-e86. PubMed ID: 28666358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
